europe neuromodulation Market

Market Introduction

Neuromodulation is the process of regulating the activity of nerves by controlling the physiological level of neurotransmitters. These modifications are brought about with the help of various devices or by drug infusion. These devices contain small electrodes that are placed on the spinal cord, brain or the peripheral nerves. Neurological disorders such as, cerebrovascular diseases, Alzheimer disease and Parkinson's disease affect the neurological functioning of the body and hence can be treated with the help of neuromodulation.

Market Overview and Dynamics

The Europe Neuromodulation market is projected to reach US$ 4,741.75 million by 2027 from US$ 2,296.33 million in 2019; it is estimated to grow with a CAGR of 9.8% from 2020 to 2027. The growth of the Europe neuromodulation market is attributed to the increasing incidence of neurological disorders, growing developments in neuromodulation technology. However, high cost of neuromodulation devices the growth of market in this region. leading to restraining the growth of the market.

Key Market Segments

Based on technology, the Europe neuromodulation market is segmented into external (non-invasive) neuromodulation and internal neuromodulation. In 2019, the internal neuromodulation segment held a larger share of the market. External (non-invasive) neuromodulation is expected to grow at a faster rate during the forecast period.

Major Sources and Companies Listed

A few major primary and secondary sources referred to while preparing the Europe neuromodulation market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.

Abbott, Boston Scientific Corporation, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., Soterix Medical Inc, Integer Holdings Corporation, and Magstim.

Reasons to buy the report

• To understand the Europe neuromodulation market landscape and identify market segments that are most likely to guarantee a strong return
• To stay ahead in comprehending the ever-changing competitive landscape of the Europe neuromodulation market
• To efficiently plan M&A and partnership deals in the Europe neuromodulation market by identifying market segments with the most promising probable sales
• To help take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments in the Europe neuromodulation market
• To obtain market revenue forecast from 2019 to 2027 in various segments of the Europe neuromodulation market

EUROPE NEUROMODULATION MARKET SEGMENTATION

By Technology

• External (Non-Invasive) Neuromodulation
  • Respiratory Electrical Stimulation
  • Transcutaneous Electrical Nerve Stimulation
  • Transcranial Magnetic Stimulation
• Internal Neuromodulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Gastric Electrical Stimulation
  • Spinal Cord Stimulation
  • Vagus Nerve Stimulation

By Application

• Chronic Pain Management
• Failed Back Syndrome
• Epilepsy
• Tremor
• Incontinence
• Depression
• Dystonia
• Gastroparesis
• Parkinson’s Disease
• Obsessive-Compulsive Disorder
• Migraine

By End User

• Hospitals
• Clinics
• Home Healthcare

By Country

• UK
• Germany
• France
• Italy
• Spain

Company Profiles

• Abbott
• Boston Scientific Corporation
• Medtronic
• NeuroPace, Inc.
• NeuroSigma, Inc.
• NEVRO CORP.
• Synapse Biomedical Inc.
• Soterix Medical Inc
• Integer Holdings Corporation

• Magstim